Evaxion Biotech: Interview about the new ObsERV platform with CEO Per Norlén(video)

Research Interview

2023-03-24

13:06

Redeye interviews CEO Per Norlén about the new ObsERV platform which identifies endogenous retroviruses as targets for personalized cancer treatment.

RR

Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.